Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy.

Pharmacol Res

Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China; Cancer Center of Zhejiang University, Hangzhou 310058, China. Electronic address:

Published: July 2021

Targeted therapy has become increasingly important and indispensable in cancer therapy. Cullin3-RING ligases (CRL3) serve as essential executors for regulating protein homeostasis in cancer development, highlighting that CRL3 might be promising targets in various cancer treatment. However, how to design new targeted therapies by disrupting the function of CRL3 is poorly understood. Here, we focus on the substrate adaptors of CRL3, and carry out a systematical research on the function of Kelch-like (KLHL) family proteins. We have identified twenty-four KLHL proteins with function of tumor promotion and thirteen KLHL proteins with high clinical significance on cancer therapy. Furthermore, we have clarified the novel biological function of KLHL13 as a vital factor that contributes to malignant progression in lung cancer. Taken together, our findings reveal multiple potential therapeutical targets and provide evidence for targeting CRL3 via KLHL substrate adaptors for cancer therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2021.105616DOI Listing

Publication Analysis

Top Keywords

cancer therapy
16
substrate adaptors
12
klhl substrate
8
adaptors cancer
8
klhl proteins
8
cancer
7
klhl
5
therapy
5
crl3
5
targeting cul3-scaffold
4

Similar Publications

Background: Prostate-specific antigen (PSA) kinetics has been investigated as a prognostic marker in post hoc analyses of clinical trials. This study validated the prognostic value of rapid and deep PSA decline in metastatic hormone-sensitive prostate cancer (mHSPC) using real-world data.

Methods: In total, 1296 patients with mHSPC were retrospectively reviewed.

View Article and Find Full Text PDF

Background: Cryoablation (cryo) is a local anti-tumor method and activation of immunity is one of its mechanisms, but it is affected by many factors. Numerous studies have proved that combination therapy based on cryo can activate immunity more effectively and synergistically. Cryo combined with chemotherapy(chemo) has been proven to improve the quality of life and prolong survival of tumor patients, but the immune effect is still unclear.

View Article and Find Full Text PDF

Further confirmation of a highly prognostic grading scheme based upon tumour budding and cell cluster size in cervical squamous cell carcinoma.

Histopathology

December 2024

Department of Surgical Pathology and Center for Uterine Cancer Diagnosis and Therapy Research of Zhejiang Province, Womens Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.

Aims: Our study aimed to further confirm the clinical significance of the tumour budding activity and cell nest size-based (TBNS) grading scheme in cervical squamous cell carcinomas (SCC).

Methods And Results: We applied the TBNS system to assess the prognostic value in an institutional cohort of well-annotated cervical SCC consisting of 312 consecutive cases with surgical resection, no neoadjuvant chemotherapy and higher than stage pT1a. We found that high budding activity, single cell and TBNS grade 3 were more frequently associated with a decreased overall survival (OS) time and disease-free survival (DFS) time (P < 0.

View Article and Find Full Text PDF

Purpose: TP53 mutations are common in head and neck squamous cell carcinoma (HNSCC). We evaluated their clinical impact in patients treated with targeted agents or immunotherapy in the KCSG HN15-16 TRIUMPH trial.

Materials And Methods: We analyzed clinical characteristics and outcomes of patients with TP53 mutations in the TRIUMPH trial, a multicenter, biomarker-driven umbrella trial in Korea.

View Article and Find Full Text PDF

Purpose: Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!